Navigation Links
BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
Date:4/10/2008

- Strategic Collaboration with the National Cancer Institute's NABTT

Consortium -

BRISBANE, Calif., April 10 /PRNewswire/ -- BiPar Sciences, Inc. today announced the expansion of the clinical program for the company's lead product candidate, BSI-201, into glioblastoma multiforme (GBM), the most common glioma in adults. BSI-201, the first poly ADP-ribose polymerase (PARP) inhibitor in BiPar's DNA repair portfolio, crosses the blood-brain barrier, a unique property that enables its targeted investigation in the brain tumor setting. This study is being conducted by investigators from the New Approaches to Brain Tumor Therapy (NABTT) consortium, a National Cancer Institute-funded research group. In addition to GBM, BiPar is currently enrolling BSI-201 in a randomized Phase 2 trial for triple-negative breast cancer and is initiating Phase 2 trials in uterine and BRCA-negative ovarian cancers.

"We believe a multi-drug strategy is the best approach to battling GBM. There is a significant need for new treatments that can offer GBM patients and their families additional hope," said Stuart A. Grossman, M.D., professor of oncology, medicine and neurological surgery at Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital and the co-chairperson for this study.

"BSI-201 is a promising agent that has been well tolerated in combination with cytotoxic therapies in patients with solid tumors and potentially addresses a key pathway by which GBM cells resist the effects of existing medications. We are hopeful that BSI-201 will safely potentiate the power of current therapies for GBM and improve survival in this difficult-to-treat cancer," said Jaishri Blakeley, M.D., Assistant Professor of Neurology, Oncology and Neurosurgery at Johns Hopkins and the study chairperson for this study.

"The scientific observations that BSI-201 crosses the blood-brain barrier and has a mechanistic basis to synergize with t
'/>"/>

SOURCE BiPar Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
2. BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor
3. BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
4. BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data
5. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
6. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
7. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
8. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
9. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2008)...ase of Test Development Program, ORANGE COUNTY, C...oulter, Inc. (NYSE: BEC ) announced today that it...bligation to Nephromics LLC, a Chestnut Hill,Mass...ense is for tests,related to the detection, monito...g cause of maternal death. In addition, Beckman Co...
(Date:8/18/2008)...re-FirstCall/ -- Micromet, Inc.,(Nasdaq: MITI ), ...rietary,antibodies for the treatment of cancer, in...bcast and conference call this morning, Monday,Au...m. Central European,Time) to discuss the blinatumo...E on August 15, 2008., To access the webcast and ...
(Date:8/14/2008)...irstCall/ -- AstraZeneca (NYSE: AZN ),today annou...al Cancer,Centre Singapore (NCCS) and the National...compounds. The collaboration, which is spelt out i...ned today, aims to further,build AstraZeneca,s dru...speed up access to new medicines of potential bene...
(Date:8/14/2008)...TE) showing clinical benefit in cancer,patients; B...ize and attack cancer...all/ -- Micromet, Inc.,(Nasdaq: MITI ), a biophar...ntibodies for the treatment of cancer, inflammatio...tion of a Phase 1 clinical study(1) on its,BiTE(R)...
Breaking Medicine Technology:Beckman Coulter Buys Out Royalty Obligation for Preeclampsia Markers 2Beckman Coulter Buys Out Royalty Obligation for Preeclampsia Markers 3Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE 2Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE 3Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE 4AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds 2AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds 3AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds 4AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds 5AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds 6Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 2Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 3Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 4Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 5Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 6HLTH and WebMD Announce Fourth Quarter Earnings Release Date and Conference Call 11176 1HLTH and WebMD Announce Fourth Quarter Earnings Release Date and Conference Call 11176 2Oncology Metrics Launches the National Practice Benchmark 3A One in a Series of Initiatives to Help Community Oncology Practices Better Measure Operat 11172 1Oncology Metrics Launches the National Practice Benchmark 3A One in a Series of Initiatives to Help Community Oncology Practices Better Measure Operat 11172 2Netsmart Technologies Extends Relationship with Manatee Glens for Enterprise Behavioral Health Software Solutions 3079 1Netsmart Technologies Extends Relationship with Manatee Glens for Enterprise Behavioral Health Software Solutions 3079 2Netsmart Technologies Extends Relationship with Manatee Glens for Enterprise Behavioral Health Software Solutions 3079 3Massive American Red Cross Tornado Relief Effort Spans Five States 11169 1Massive American Red Cross Tornado Relief Effort Spans Five States 11169 2
...s large multi-site lab faced challenges with manua...agement challenges which were exacerbated by staf...ized that better document control was essential fo...r laboratorians to more efficiently access and man...f Quality Management software packages and evaluat...
...Editor ,According to the American Diabetes Ass...es in 2002 was estimated to be $132 billion, or on... United States. A chronic disease with no cure, di...ype 2, and gestational) marked by high levels of b...duction, insulin action, or both. Nearly 20 millio...
Other Medicine Technology:Choosing Lab Quality Management Software 2Choosing Lab Quality Management Software 3Choosing Lab Quality Management Software 4Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control 2Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control 3
(Date:8/20/2008)...WTON, Mass., Aug. 20 /PRNewswire/ -- Questex Media...siness media company and owner of,American Spa and... the,International Beauty Shows, the International...d the SPATEC appointment events today announced th... portals SpaTrade (, http://www.SpaTrade.com ) an...
(Date:8/20/2008)...r in secondary life insurance market ranked 156 am...in America on Inc. 500 list, BETHESDA, Md., Aug. ...der in the secondary life insurance market, announ...growing insurance related company in the US by,Inc... 2008 Inc. 500 list of,fastest growing companies i...
(Date:8/20/2008)...UTHFIELD, Mich., Aug. 20 /PRNewswire/ -- WXYZ- TV/... Wellness Promotion will give thousands of,Detroit..."HEALTHY LIVING,FOR KIDS" program. This year the p...0 a.m. to 5 p.m. at the Charles H. Wright Museum o... 1977, "Healthy Living for Kids",has provided free...
(Date:8/20/2008)...LWAUKEE, Aug. 20 /PRNewswire/ -- Fourteen physicia...p have announced that they plan to enhance,the car...ining Aurora,Health Care., "These are top-notch p...have decided to join our organization," said Nick ...ve officer. "We look forward to working with,them ...
Breaking Medicine News(10 mins):Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 2Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 3Health News:Integrity Capital Partners Ranked 2nd Fastest Growing Insurance Related Company in US by Inc. Magazine 2Health News:WXYZ-TV/Channel 7 is 'On Your Side' With Healthy Living For Kids; Free Immunizations for Children on Sunday, August 24 at Charles H. Wright Museum of African American History 2Health News:WXYZ-TV/Channel 7 is 'On Your Side' With Healthy Living For Kids; Free Immunizations for Children on Sunday, August 24 at Charles H. Wright Museum of African American History 3Health News:Commonwealth Medical Group Physicians to Join Aurora Health Care 2
...a, high blood pressure or depression are more like...earchers at the University of Texas,// have survey...ars of age. They found that the partners of those ... per cent more likely to have these problems thems...
... could soon be procurable in the doctor's office o...drug responses. Researchers at LGC// (Laboratory o...duce a DNA test kit which uses saliva, blood or ur...n 15 to 20 minutes. The device has been made smal...
...f Texas feel that they may have found an effective...hat threatens clear vision.// Using photodynamic t...n three patients who were suffering from intraocul...ed serious retinal detachments. Intraocular choroi...
... observed that nearly one out of every five medica...s may be in error. The problem occurs regardless o...e nation's leading health care accrediting organiz...ne released a report titled, "To Err is Human: Bui...
Other Medicine News:
...r is a multi-lumen, over-the-wire thrombectomy cat...al of fresh, soft thrombus in dialysis shunts. The...y alternative to surgery and thrombolytic therapy....jector. Fragments and removes thrombus to help re...
Introduced more than 30 years ago by Dr. Thomas J. Fogarty, these embolectomy catheters are indicated for the removal of fresh, soft emboli and thrombi from vessels in the arterial system.
...tomy catheter is designed to offer the ultimate in...eate a low pressure zone around the catheter tip c... catheter, where it is fragmented by the jets, and...vides rapid restoration of flow in minutes, as opp...
When combined with a stimulation lead system, the Model 3077 SSI Temporary Pacemaker can be used whenever temporary atrial or ventricular pacing is indicated. The device can be employed for therapeut
Medicine Products: